Studies in ALL patients have demonstrated that the greater the inhibition of de novo purine synthesis, the greater the anti-leukaemic effects observed.45 We might also have expected decreased toxicity in this subgroup of patients, due to the increased formation of inactive metabolites due to their high TPMT status. Here, TPMT is linked to acute lymphoblastic leukemia.